Aprea Therapeutics (APRE) Depreciation & Amortization (CF) (2018 - 2026)
Aprea Therapeutics (APRE) posted quarterly Depreciation & Amortization (CF) of $5428.0 for Q1 2026, little changed year-over-year from $5429.0 in Q1 2025, and little changed quarter-over-quarter from $5429.0 in Q4 2025.
Aprea Therapeutics (APRE) Depreciation & Amortization (CF) (2018 - 2026) Analysis & Trends
Aprea Therapeutics (APRE) has reported Depreciation & Amortization (CF) for 9 consecutive years, with $5428.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) changed 0.02% year-over-year to $5428.0; the TTM figure through Mar 2026 stood at $21714.0 (up 0.57% YoY), while the FY2025 annual figure was $21715.0, down 2.7% from the prior year.
- Depreciation & Amortization (CF) steadied at $5428.0 in Q1 2026 per APRE's latest filing, from $5429.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $6157.0 in Q1 2024 and bottomed at -$2385.0 in Q4 2022.
- Historically, Depreciation & Amortization (CF) has averaged $3583.3 across 5 years, with a median of $5304.0 in 2024.
- Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) tumbled 180.33% — and 2024, when it surged 2267.86%.
- Aprea Therapeutics' Depreciation & Amortization (CF) stood at -$2385.0 in 2022, then jumped by 309.06% to $4986.0 in 2023, then gained by 8.86% to $5428.0 in 2024, then grew by 0.02% to $5429.0 in 2025, then dropped by 0.02% to $5428.0 in 2026.
- Business Quant data shows APRE's Depreciation & Amortization (CF) at $5428.0 in Q1 2026, $5429.0 in Q4 2025, and $5429.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Aprea Therapeutics | 34.25 Mn | 34.25 Mn | - | 5,746.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5,746.00 |
| Jun 30, 2026 | 5,746.00 |
| Mar 31, 2026 | 5,428.00 |
| Mar 31, 2026 | 5,428.00 |
| Dec 31, 2025 | 5,429.00 |
| Dec 31, 2025 | 5,429.00 |
| Sep 30, 2025 | 5,429.00 |
| Sep 30, 2025 | 5,429.00 |
| Jun 30, 2025 | 5,428.00 |
| Jun 30, 2025 | 5,428.00 |
| Mar 31, 2025 | 5,429.00 |
| Mar 31, 2025 | 5,429.00 |
| Dec 31, 2024 | 5,428.00 |
| Dec 31, 2024 | 5,428.00 |
| Sep 30, 2024 | 5,429.00 |
| Sep 30, 2024 | 5,429.00 |
| Jun 30, 2024 | 5,304.00 |
| Jun 30, 2024 | 5,304.00 |
| Mar 31, 2024 | 6,157.00 |
| Mar 31, 2024 | 6,157.00 |